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We investigated the impact of patient and disease characteristics, including cytogenetics, previous therapy,
and depth of response, on the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for
patients with myelodysplastic syndrome (MDS). We analyzed 256 MDS patients who underwent trans-
plantation from a matched related (n ¼ 133) or matched unrelated (n ¼ 123) donor after 2001. Of the 256, 78
(30.5%) did not receive cytoreductive therapy before HSCT; 40 (15.6%) received chemotherapy, 122 (47.7%)
received hypomethylating agents (HMA), and 16 (6.2%) received both (chemoþHMA). Disease status at HSCT
deﬁned by International Working Criteria was complete remission in 46 (18%) patients. There were signiﬁcant
differences between therapy groups: there were more therapy-related MDS and higher use of matched
related donor in the untreated group. The chemotherapy group had higher serum ferritin levels at HSCT.
Patients were older and had more high-risk disease by revised International Prognostic Scoring in the HMA
group. Despite those differences, transplantation outcomes were similar in patients who were untreated and
who received cytoreductive therapy before HSCT. Three-year event-free survival (EFS) was 44.2%, 30.6%,
34.2%, and 32.8% for untreated, chemotherapy, HMA, and chemoþHMA groups, respectively (P ¼ .50).
Multivariate analyses revealed that older age (hazard ratio [HR], 1.3; P ¼ .001); high-risk histologic subtypes,
including refractory anemia with excess blasts (HR, 1.5; P ¼ .05) and chronic myelomonocytic leukemia (HR,
2.1; P ¼ .03), high-risk cytogenetics with monosomal karyotype (MK) (HR, 4.0; P < .0001) and high serum
ferritin level at HSCT (HR, 1.8; P ¼ .002) were poor prognostic factors for EFS. Bone marrow blast count 5% or
higher at HSCT (HR, 1.6; P ¼ .01) and MK (HR, 4.2; P < .0001) were the only prognostic factors for increased
relapse incidence after HSCT. Patients with MK represented a poor prognostic group, with 3-year EFS of 11.4%
and relapse incidence of 60.9%. In this analysis, various therapy approaches before HSCT did not lead to
different transplantation outcomes. Cytogenetics deﬁned by MK was able to identify a very poor prognostic
groups that innovative transplantation approaches to improve outcomes are urgently needed.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Myelodysplastic syndromes (MDS) comprise a family of
clonal hematopoietic diseases characterized by bone marrow
failure and a predisposition to evolve into acute myeloid
leukemia (AML) [1]. Despite major progress in understanding
its pathophysiology and recent advances in treatment,edgments on page 1624.
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2014 American Society for Blood and Marrow
14.06.022particularly with hypomethylating agents (HMAs), MDS re-
mains incurable with standard forms of treatment. Allogeneic
hematopoietic stem cell transplantation (HSCT) is the only
therapeutic option that has the potential to produce long-
term remission, with disease-free survival of 25% to 60%,
depending on disease characteristics [2-4]. Themajor cause of
treatment failure after HSCT in MDS is relapse of the disease.
Cytogenetic abnormalities and theproportionof bonemarrow
myeloblasts are known to predict the risk of relapse after
HSCT. Cytoreductive therapy is commonly used before referral
for HSCT, with a goal of reducing risk of disease relapse after
transplantation. The effectiveness of chemotherapy and/or
HMA treatment before HSCT is not established.Transplantation.
B. Oran et al. / Biol Blood Marrow Transplant 20 (2014) 1618e1625 1619In the present analyses, we sought to determine the
impact of disease characteristics at diagnosis and at HSCT,
including pretransplantation MDS therapy and depth of




We retrospectively analyzed 256 patients, 18 years or older, who were
diagnosed with MDS and underwent ﬁrst HSCT at the University of Texas
MD Anderson Cancer Center from January 1, 2001 to December 31, 2012.
Histological subtypes were classiﬁed according to the World Health Orga-
nization deﬁnition [5]. Forty patients (15.6%) with refractory anemia (RA) or
RA with ringed sideroblasts and 34 (13.7%) with refractory cytopenia withTable 1





Age, median (IQR), yr 56 (48-62) 52 (45-57)
WHO histological subtype
Low/intermediate 74 (28.9) 27 (34.6)
High risk 100 (39.1) 13 (16.7)
CMML 23 (9.0) 3 (3.8)
MDS-U 59 (23.0) 35 (44.9)
T-MDS 92 (35.9) 43 (55.1)
Cytogenetics by 5-group risk n ¼ 254
Very good/good 105 (41.3) 27 (35.1)
Intermediate 32 (12.6) 9 (11.7)
Poor 46 (18.1) 22 (28.4)
Very poor 71 (28.0) 19 (24.7)
MK n ¼ 254
CN 102 (40.2) 27 (35.1)
MK 79 (31.1) 30 (39.0)
MKþ 73 (28.7) 20 (25.9)
IPSS-R at diagnosis n ¼ 144
Very low/low 40 (27.8) 11 (32.4)
Intermediate 18 (12.5) 6 (21.8)
High 22 (15.3) 6 (20.5)
Very high 37 (25.7) 2 (14.1)
Missing 27 (18.8) 9 (16.7)
Morphological response by IWG* n ¼ 178
CR 46 (25.8)
AD 132 (74.2)
Persistent karyotype abnormality at HSCTy n ¼ 106
No 35 (33.0)
Yes 71 (67.0)
BM blast at HSCT, %
<5 169 (66.0) 55 (70.5)
5 87 (34.0) 23 (29.5)
Ferritin level n ¼ 201 n ¼ 47
Median, IQR 1131 (521-2246) 1077 (389-263
Stem cell source
PB 169 (66.0) 56 (71.8)
BM 87 (34.0) 22 (28.2)
Donor source
MRD 133 (52.0) 54 (69.2)
MUD 123 (48.0) 24 (30.8)
Conditioning regimen
MAC 162 (63.3) 55 (70.5)
RIC 94 (36.7) 23 (29.5)
Time to HSCT from diagnosis, months
Median, IQR 8 (5.2-15.3) 5.5 (3.4-12.5
Transplantation yr
Before 2005 62 (24.2) 36 (46.1)
After 2005 194 (75.8) 42 (53.9)
Median follow-up of survivors, months
Median, IQR 33.9 (17-63.4) 38.4 (18.1-73.
HSCT indicates hematopoietic stem cell transplantation; WHO, World Health Org
chronic myelomonocytic leukemia, MDS-U, myelodysplastic syndrome unclassiﬁa
ternational Prognostic Scoring System-Revised; IWG, International Working Grou
MUD, matched unrelated donor; MAC, myeloablative conditioning; RIC, reduced in
Data presented are n (%) unless otherwise indicated.
* Only patients who received MDS therapy before HSCT were included.
y Only patients with abnormal cytogenetics and who had cytogenetic evaluationmultilineage dysplasia were grouped as “low/intermediate risk” histology,
whereas 45 (17.6%) with RA with excess blasts type 1 and 55 (21.5%) with
RA with excess blasts type 2 were grouped as “high-risk” (Table 1). The
histological subtype was MDS-unclassiﬁable (MDS-U) in 59 cases (23.2%),
and 23 patients (9%) had chronic myelomonocytic leukemia (CMML).
Cytogenetic ﬁndings were classiﬁed according to the 5-group classiﬁcation
recently described by Schanz et al. [6] and monosomal karyotype (MK) re-
ported by Breems et al. [7]. Patients were categorized according to the
revised International Prognostic Scoring System (IPSS-R) by disease char-
acteristics at diagnosis [8]. CMML and therapy-related MDS (t-MDS) were
not included in this risk scoring, per deﬁnition.
Prior Therapy for MDS and Response Evaluation
Of the 256 patients included in the study, 178 (69.5%) received treat-







55 (44-60) 59 (53-64) 59 (56-60) .0001
7 (17.5) 38 (31.2) 2 (12.5)
26 (65.0) 51 (41.8) 10 (62.5)
4 (10.0) 12 (9.8) 4 (25.0)
3 (7.5) 21 (17.2) 0 <.001
12 (30.0) 37 (30.3) 0 <.001
19 (47.5) 52 (43.0) 7 (43.7)
6 (15.0) 13 (10.7) 4 (25.0)
5 (12.5) 18 (14.9) 1 (6.3)
10 (25.0) 38 (31.4) 4 (25.0) .20
17 (42.5) 51 (42.1) 7 (43.8)
14 (35.0) 29 (24.0) 6 (37.5)
9 (22.5) 41 (33.9) 3 (18.7) .30
2 (8.4) 23 (31.1) 4 (33.3)
5 (20.8) 5 (6.8) 2 (16.7)
6 (25.0) 9 (12.2) 1 (8.3)
6 (25.0) 25 (33.8) 4 (33.3)
5 (20.8) 12 (16.2) 1 (8.3) .03
12 (30.0) 31 (25.4) 3 (18.8)
28 (70.0) 91 (74.6) 13 (81.2) .70
9 (37.5) 24 (33.3) 2 (20)
15 (62.5) 48 (66.7) 8 (80) .60
25 (62.5) 79 (64.8) 10 (62.5)
15 (37.5) 43 (35.2) 6 (37.5) .80
n ¼ 21 n ¼ 118 n ¼ 15
7) 1555 (1100-2503) 997 (425-2010) 1748 (1002-3211) .03
22 (55.0) 78 (63.9) 13 (81.3)
18 (45.0) 44 (36.1) 3 (18.7) .20
19 (47.5) 52 (42.6) 8 (50.0)
21 (52.5) 70 (57.4) 8 (50.0) .003
24 (60.0) 72 (59.0) 11 (68.8)
16 (40.0) 50 (41.0) 5 (31.2) .40
) 6.9 (5.5-12.3) 9.0 (6.0-16.8) 12.7 (6.8-32.9) .0001
26 (65.0) 0 0
14 (35.0) 122 (100) 16 (100) <.001
4) 88.3 (51.6-125.1) 26.6 (15.5-45) 25.9 (16.6-58.5) .01
anization; HMA, hypomethylating agents; IQR, interquartile range; CMML,
ble; t-MDS, therapy-related MDS; MK, monosomal karyotype; IPSS-R; In-
p; PB, peripheral blood; BM, bone marrow; MRD, matched related donor;
tensity conditioning.
at HSCT were included.
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Patients who received cytoreductive therapy were further categorized by
the treatment received: 40 (15.6%) only chemotherapy (chemo), 122
(47.6%) only HMA, and 16 (6.3%) both chemotherapy and an HMA (che-
moþHMA) before HSCT. Disease status at HSCT was deﬁned by Interna-
tional Working Group (IWG) criteria [9] for patients who received prior
therapy for MDS.
Hematopoietic Stem Cells Allograft Characteristics
The source of hematopoietic stem cells was peripheral blood in 169
patients (66%) and bonemarrow (BM) in 87 patients (34%). Serologic or low-
resolution molecular techniques were used for class I antigens and high-
resolution molecular typing using polymerase chain reaction for class II
alleles for human leukocyte antigen typing was used until July 2005. After
July 2005, all donors had high-resolution molecular typing of class I and II
antigens. Of 256, 133 (52%) had matched unrelated donors (MUD) that were
classiﬁed based on HLA typing, as described by Weisdorf et al [10]. The rest
had a matched related donor (MRD).
Conditioning regimens varied but were ﬂudarabine and busulfan
based in 195 (76.2%) or ﬂudarabine and melphalan based in 61 (23.8%)
patients. The impact of conditioning regimens on outcomes was analyzed
by their dose intensity, using Center for International Bone Marrow and
Transplant Research criteria for reduced-intensity (RIC) versus myeloa-
blative preparative regimens [11]. Of 94 patients with RIC, 55 (58.5%)
were age 60 or older in contrast to 31 of 162 (19.1%) patients with mye-
loablative conditioning (P < .001). Tacrolimus and methotrexate were
used as graft-versus-host disease prophylaxis in the majority of the pa-
tients (90.7%). Treatment protocols and this retrospective analysis were
approved by the University of Texas MD Anderson Cancer Center Insti-
tutional Review Board. All patients provided written informed consent for
the treatment.
Endpoints and Deﬁnitions
The primary endpoints were relapse incidence (RI), transplantation-
related mortality (TRM), event-free survival (EFS), and overall survival
(OS). All outcomes were measured from the time of stem cell infusion.
Relapse was deﬁned as hematologic recurrence of MDS according to stan-
dardized criteria [9]. TRMwas death from causes other than relapse of MDS.
For analyses of EFS, treatment was considered a failure at the time of relapse
or at the time of death from any cause; data for patients who were alive and
in complete remission (CR) were censored at the date of last contact. OS was
based on death from any cause; surviving patients were censored at the date
of last contact. Cumulative incidence was used to estimate the endpoints of
RI and TRM. EFS and OS were calculated using the Kaplan-Meier method.
Univariate comparisons of all endpoints were completed by the log-rank
test. A Cox proportional hazards model [12] or the Fine and Gray method
[13] for competing hazards was used for multivariate regression. Variables
were included in the multivariate model if they were conceptually impor-
tant, if they approached P < .10, or if they attained statistical signiﬁcance in
the univariate regression. All factors were tested for the proportional
hazards assumption. Analyses were performed using Stata version 11.2 for
Windows (StataCorp, College Station, TX).
RESULTS
Patient and disease characteristics of the study cohort and
by each pretransplantation MDS therapy approach are pre-
sented in Table 1. The median age at HSCT was 56 years
(interquartile range [IQR], 48 to 62 years) and 86 patients
(33.6%) were age 60 or older. Our study cohort had high-risk
features, including 92 patients (35.9%) with t-MDS and 100
(39.1%) with high-risk histology. Fifty-nine of 144 patients
(40.1%) evaluable for IPSS-R were in the high or very high-
risk group by IPSS-R at diagnosis. At HSCT, the median BM
blast count was 3% (IQR, 1 to 7), and 39 patients (15.3%) had a
blast count of 10% or more. The median pretransplantation
ferritin level was 1131 mg/L (IQR, 521 to 2334). The median
time from MDS diagnosis to HSCT was 8 months (IQR, 5.2 to
15.3 months).
There were differences observed between therapy
groups. Patients who received HMA before HSCT were older
and had more high or very high-risk disease by IPSS-R
compared with the rest of the cohort. Patients who re-
ceived chemotherapy had a higher serum ferritin level at
HSCT. Untreated patients had a greater proportion of t-MDSand MDS-unclassiﬁed at diagnosis and proceeded with
HSCT within a shorter period of time after diagnosis, and
more often with an MRD. There was also a difference in the
date of transplantation between therapy groups. Of 62 pa-
tients who underwent transplantation before 2005, 36 were
untreated (58.1%) and the rest received chemotherapy only.
After 2005, when HMA became available, of 194 MDS pa-
tients who underwent transplantation, only 42 were un-
treated (21.7%) and 14 (7.2%) received chemotherapy only.
The majority of the patients, 122 of 194 (63.4%), received
only HMA after 2005.
Cytogenetic Abnormalities
Approximately one half of the cohort had high-risk cy-
togenetics (Table 1). MK and 5-group cytogenetic classiﬁca-
tion overlapped signiﬁcantly, as 63 of 73 (86.3%) MK-positive
(MKþ) patients were in the “very poor” group and all pa-
tients with normal cytogenetics (CN) were in “good” risk
groups (P< .001). Among 96MK-negative (MK) patients, 20
(20.8%) were in “good,” 32 (33.3%) in “intermediate,” 36
(37.5%) in “poor,” and 8 (8.3%) in “very poor” risk groups by
5-group cytogenetic classiﬁcation. Complex karyotype was
also signiﬁcantly associated with MK, as 66 of 73 of MKþ
patients (90.4%) had complex karyotype (P < .0001).
The distribution of high-risk cytogenetics was similar
between low/intermediate and high-risk histology groups
(P ¼ .10). However, CMML was different; 13 of 23 (56.5%) had
CN and only 1 patient had MKþ. Of 92 t-MDS patients, 36
(39.1%) had MK and 44 (47.8%) had MKþ, whereas 60 (37%)
and 29 (17.9%) of the rest had MK and MKþ, respectively
(P < .001).
MDS Therapy before HSCT
One hundred and seventy-eight patients received MDS
therapy before HSCT. Forty-six (25.8%) achieved CR, 29
(16.3%) had marrow CR, 63 (35.4%) had stable disease, and 40
(22.5%) had progressive disease before HSCT. Patients not in
CR were grouped together as active disease (AD) at HSCT.
There was no difference among different therapy groups in
achieving CR at HSCT (P ¼ .70). Similarly, the rate of CR at
HSCTwas comparable in different cytogenetic risk groups. By
IWG criteria, 18.9% of CN, 14.9% of MK, and 21.9% of MKþ
patients were in CR (P ¼ .30).
The persistence of the abnormal cytogenetic clone at
HSCT was evaluated in 113 patients who had cytogenetic
abnormalities and received MDS therapy before HSCT. Of
these 113, 106 were evaluable for cytogenetic response; 35
(33%) had a normal karyotype at transplantation whereas 71
(67%) had persistence of the abnormal clone detected at
diagnosis. There was no difference among different therapy
groups in achieving cytogenetic remission (P ¼ .60). Simi-
larly, the rate of cytogenetic remission after MDS therapy at
HSCT was comparable in different cytogenetic risk groups;
32.1% of MK and 30.8% of MKþ patients were in cytogenetic
remission at HSCT (P ¼ .80).
Disease Outcomes
Overall, 112 patients were alive at last follow-up, with a
median survival of 34 months (IQR, 17 to 63 months). One
hundred (89.3%) were alive and free of disease at their last
follow-up. RI was 34.1% at 3 years (95% conﬁdence interval
[CI], 28.0% to 40.2%) and most relapses occurred within the
ﬁrst year after HSCT, with an incidence of 27.7% (95% CI, 22.4%
to 33.3%). The incidence of TRM at 3-year was 29.3% (95% CI,
Table 2
Univariate results for RI, TRM, EFS, and OS
Variable RI TRM EFS OS
HR P Value HR P Value HR P Value HR P Value
Age, per 10 yr 1.06 .50 1.4 .002 1.3 .002 1.3 .002
WHO histological subtype
Low/intermediate Ref Ref Ref Ref
High risk 2.0 .02 1.0 .90 1.6 .02 1.5 .05
CMML 1.5 .30 1.4 .40 1.6 .10 1.5 .20
MDS-U 1.0 .90 1.4 .20 1.3 .20 1.3 .20
T-MDS 1.4 .10 1.2 .40 1.5 .02 1.5 .01
Cytogenetics by 5-group risk
Very good/good Ref Ref Ref Ref
Intermediate 1.2 .70 1.4 .40 1.4 .20 1.3 .30
Poor 1.4 .40 1.2 .50 1.4 .20 1.6 .06
Very poor 3.9 <.0001 1.1 .60 3.4 <.0001 3.3 <.0001
MK
CN Ref Ref Ref Ref
MK 1.2 .50 1.4 .20 1.5 .06 1.6 .03
MKþ 4.1 <.0001 1.2 .50 3.7 <.0001 3.7 <.0001
Previous therapy for MDS
Untreated Ref Ref Ref Ref
Chemo only 1.1 .70 1.5 .30 1.4 .20 1.4 .20
HMA only 1.0 .90 1.5 .10 1.3 .20 1.4 .10
ChemoþHMA .8 .70 1.8 .20 1.2 .50 1.5 .30
Response by IWG at HSCT
CR Ref Ref Ref Ref
AD .8 .30 1.7 .10 1.1 .50 1.3 .20
Untreated .8 .50 1.0 .90 .8 .50 .9 .60
Cytogenetic remission
Yes Ref Ref Ref Ref
No 1.2 .60 1.0 .90 1.3 .20 1.5 .10
BM blast at HSCT
<5% ref Ref Ref Ref
5% 2.0 .01 .9 .80 1.6 .006 1.6 .006
Ferritin level
1130 Ref Ref Ref Ref
>1130 1.0 .80 2.0 .009 1.6 .01 2.0 .001
Missing 1.7 .06 1.2 .60 1.5 .05 1.7 .02
Stem cell source
PB Ref Ref Ref Ref
BM .9 .90 1.4 .20 1.2 .30 1.3 .10
Donor source
MRD ref Ref ref Ref
MUD .7 .20 1.7 .02 1.2 .30 1.4 .06
Conditioning regimen
MAC Ref Ref ref
RIC .6 .05 2.1 .001 1.2 .20 1.2 .40
Time to transplantation after diagnosis
8 months Ref Ref ref
>8 months .6 .03 1.2 .50 .8 .10 .8 .10
Transplantation yr
Before 2005 Ref Ref Ref Ref
After 2005 .8 .30 .8 .40 .7 .10 .7 .10
RI, relapse incidence; TRM, transplant related mortality; EFS, event-free survival; OS, overall survival; HR, hazard ratio; WHO, World Health Organization; Ref,
reference; CMML, Chronic myelomonocytic leukemia; MDS-U, MDS-unclassiﬁable; t-MDS; therapy-related MDS; MK, monosomal karyotype; HMA, hypo-
methylating agents; IWG, International Working Group; HSCT, hematopoietic stem cell transplant; CR, complete remission; AD, active disease; BM, bone
marrow; PB, peripheral blood; BM, bonemarrow;MRD, matched related donor; MUD,matched unrelated donor; MAC, myeloablative conditioning; RIC, reduced
intensity conditioning.
B. Oran et al. / Biol Blood Marrow Transplant 20 (2014) 1618e1625 162123.5% to 34.3%). Three-year EFS and OS were 36.6% (95% CI,
30.3% to 43%) and 41.6% (95% CI, 34.9% to 48.1%), respectively.
Univariate Analyses
Relapse and TRM
As summarized in Table 2, high-risk histology, high-risk
cytogenetic deﬁned by any of the 2 classiﬁcations schemas
at diagnosis, as well as BM blast count of 5% or greater at
HSCTwere associatedwith increased risk of relapse (Table 2).
Signiﬁcant prognostic factors for increased TRM were older
age, serum ferritin levels >1130 mg/L at HSCT, and the use of
MUD versus MRD. The use of a RIC conditioning regimen,
which was signiﬁcantly associated with older age (P < .001),was also found to increase TRM. HSCT after 2005 did not
decrease TRM signiﬁcantly in univariate analysis.
EFS
The median EFS was 12.6 months (IQR, 3.6 to not
reached). Older age, high-risk histology, t-MDS, high-risk
cytogenetic deﬁned by any of the 2 classiﬁcations schemas
at diagnosis, BM blast count of 5% or higher, and serum
ferritin levels >1130 mg/L at HSCT were associated with
decreased EFS. MKwas able to identify 3 different risk groups
for EFS, whereas 5-group identiﬁed 2 risk groups. HSCT after
2005 was associated with improved EFS but that did not
reach statistical signiﬁcance.
B. Oran et al. / Biol Blood Marrow Transplant 20 (2014) 1618e16251622Overall survival
The median OS was 20.1 months (IQR, 6.3 to not
reached). Older age, high-risk histology, t-MDS, BM blast
count of 5% or higher, and serum ferritin levels > 1150 mg/L
at HSCT were also associated with inferior OS. Trans-
plantationwith anMUD decreased OS compared with use of
an MRD. Similar to EFS, MK was able to identify 3 different
risk groups for OS whereas 5-group cytogenetic classiﬁca-
tion identiﬁed 2 risk groups (Table 2). HSCT after 2005 was
associated with improved OS, but that did not reach sta-
tistical signiﬁcance.
The impact of previous therapy on HSCT outcomes
The transplantation outcomes were similar between
different therapy groups, including untreated patients
(Table 2). Similarly, patients in CR, those with AD at HSCT
after MDS therapy, and untreated patients had similar RI,
TRM, EFS, and OS. Focusing on the 144 patients who had BM
blasts of 5% or higher at any time point during the course of
their disease, we compared 34 patients in CR at HSCTwith 86
who had AD and 24 untreated patients. Patients with AD at
HSCT had increased TRM (hazard ratio [HR], 2.6; P ¼ .03),
whereas RI (HR, .6; P¼ .20), EFS (HR,1.2; P¼ .40), and OS (HR,
1.5; P ¼ .10) were not statistically different compared with
those who underwent transplantation in CR. All trans-
plantation outcomes, including TRM (HR,1.4; P¼ .50), RI (HR,
.7; P¼ .40), EFS (HR, .9; P¼ .80), and OS (HR,1.0; P¼ .90) were
comparable for patients who were untreated compared with
CR patients. Among 112 patients who never had BM blast
count of 5% or higher during their disease course, we did not
observe any difference for any transplantation outcomes
between 13 patients in CR at HSCT, 47 who had AD, and 54
untreated patients.
Similar to morphologic response to MDS therapy, cyto-
genetic remission among patients with cytogenetic abnor-
malities did not lead to superior outcomes compared with
those with persistence of the abnormal cytogenetic clone.
We did not observe a difference in RI, TRM, EFS, and OS
between patients with and without persistence of the
abnormal cytogenetic clone (P ¼ .60, P ¼ .90, P ¼ .20, P ¼ .10,
respectively).Figure 1. Cumulative relapse incidence (A) and EFS (B) after hematopoietic stem cel
siﬁcation with monosomal karyotype (MK) was able to identify 3 difference risk group
(A) MKþ patients composed a very high-risk group with 3-year RI of 60.9% in contras
patients composed an intermediate-risk group with 3-year RI of 26.7%. (B) EFS was
respectively.The impact of donor type and year of transplantation on
HSCT outcomes
In our cohort, all unrelated donors had high-resolution
molecular typing of class I and II antigens after July 2005. To
investigate the impact of better allele-level matching on MUD
transplantation outcomes, we used the transplantation year
(before 2005 versus after 2005) as a surrogate marker. MRD
patients served as a control group, as they had no change in
HLA typing and selection algorithmover the same time period.
TRM at 3 years improved from 53.4% to 34.9% after 2005
for MUD (HR, .6; P ¼ .10), whereas no improvement was
observed for MRD patients; 3-year TRM was 26.8% before
2005 and 21.7% after 2005 (HR, .8; P ¼ .50). For MUD, sig-
niﬁcant improvements for both EFS and OS were observed
after 2005; the 3-year EFS increased from 17.7% to 37.9% (HR,
.6; P¼ .06) and 3-year OS from 17.7% to 39.9% (HR, .5; P¼ .03).
For MRD, 3-year EFS increased from 32% to 41.2% (HR, .8;
P ¼ .30) and 3-year OS from 38.7% to 50% (HR, .8; P ¼ .30);
those differences were statistically not signiﬁcant.
Multivariate Analyses
Multivariate models conﬁrmed the role of high-risk cy-
togenetics, deﬁned as MKþ or very high risk by 5-risk group
classiﬁcation, on RI, EFS, and OS (Figure 1A,B). In Table 3, we
present the models with MK because of its potential to
identify 3 risk groups for EFS and OS in a linear fashion.
Among patient and disease characteristics, older age, high-
risk cytogenetics with MKþ, histological subtype of CMML,
and high serum ferritin level at HSCT decreased both EFS and
OS, compared with low/intermediate risk histology and low
serum ferritin level at HSCT, respectively. MKþ also was a
poor prognostic factor for relapse incidence, as was a BM
blast count of 5% or higher at HSCT. Among transplantation-
related variables, the use of an MUD was associated with
increased TRM and decreased OS. HSCT after 2005 was
associated with decreased TRM and signiﬁcantly improved
EFS and OS.
DISCUSSION
Our study, conducted at a single center with a relatively
large cohort of MDS patients, demonstrates importantl transplantation by monosomal karyotype in MDS patients. Cytogenetic clas-
s for MDS patients who had allogeneic hematopoietic stem cell transplantation.
t to good-risk normal cytogenetics (CN) patients with 3-year RI of 16.9%. MK
similar; MKþ, MK, and CN patients had 3-year EFS of 11.4%, 30%, and 62.3%,
Table 3
Multivariate analyses for RI, TRM, EFS, and OS
Variable RI* TRMy EFSz OSx
HR P Value HR P Value HR P Value HR P Value
Age, per 10 yr 1.3 .04 1.4 <.001 1.4 <.001
WHO histological subtype NS
Low/intermediate risk 1.0 1.0
High risk 1.8 .007 1.7 .01
CMML 2.3 .009 2.3 .01
MDS-U 1.6 .08 1.6 .09
MK
CN 1.0 1.0 1.0
MK 1.3 .40 1.9 .005 1.7 .02
MKþ 4.2 <.0001 5.2 <.001 4.9 <.0001
Ferritin level
1150 1.0 1.0 1.0
>1150 1.7 .06 1.8 .002 2.2 <.001
Missing .7 .40 1.0 .90 1.1 .20
BM blast at HSCT NS
<5% 1.0 1.0 1.0
5% 1.6 .01 1.2 .30 1.3 .20
Donor
MRD 1.0 1.0
MUD 1.8 .02 1.6 .01
Transplantation yr
Before 2005 1.0 1.0 1.0
After 2005 .4 .006 .4 .002 .4 .001
NS indicates not signiﬁcant.
* RI is adjusted for histological subtype, MK, bone marrow blast count at HSCT, conditioning intensity, and time to HSCT.
y TRM is adjusted for age, serum ferritin level at HSCT, donor type, conditioning intensity, and transplantation year.
z EFS is adjusted for age, histological subtype, t-MDS, MK, serum ferritin, bone marrow blast count at HSCT and transplantation year.
x OS is adjusted for age, histological subtype, t-MDS, MK, serum ferritin and bone marrow blast count at HSCT, donor type, and transplantation year.
B. Oran et al. / Biol Blood Marrow Transplant 20 (2014) 1618e1625 1623ﬁndings, including the following: (1) high-risk cytogenetic
abnormalities at diagnosis determine prognosis after HSCT,
(2) unrelated donor transplantations have inferior OS and
higher TRM, compared with transplantations from a
matched related donor and, (3) in patients treated with
HMAs and/or chemotherapy and who have not progressed to
AML, response to treatment before HSCTmay not affect post-
transplantation outcomes.
One of the most striking ﬁndings in the present study was
the reliable and reproducible identiﬁcation of a very poor
prognosis group by the MK classiﬁcation [7], which was
developed for the prognostication of AML patients who did
not undergo transplantation, and the 5-group classiﬁcation
developed for primary MDS patients [6]. MKþ patients
composed a very high-risk group, with 3-year RI of 60.9%, EFS
of 11.4%, and OS of 15.8%. This is in contrast to good-risk CN
patients with 3-year RI of 16.9%, EFS of 62.3%, and OS of
65.1%. MK patients composed an intermediate-risk group,
with 3-year RI of 26.7%, EFS of 30%, and OS of 38.8%.
The presence of MKþ cytogenetic abnormalities has been
associated with poor prognosis in patients with MDS [12,13].
Similar to our ﬁndings, recent reports also suggested that
patients with MKþ also have increased risk of relapse with
increasedmortality after transplantation [14,15]. The Spanish
Registry for MDS [16] reported a strong association of MK
with complex karyotype and suggested that it is the com-
plexity of the karyotype (ie, number of chromosomal ab-
normalities) that is prognostic for worse outcomes inMDS. In
our cohort, we could not test that hypothesis because of the
small number of MKþ patients without complex karyotype
abnormalities. Our results and other reports suggest that MK
and the 5-group cytogenetic risk classiﬁcation schemas are
more predictive for post-transplantation outcomes than the
International Prognostic Scoring System cytogenetic classi-
ﬁcation in MDS patients.We showed that unrelated donor transplantations had
inferior OS and higher cumulative incidences of TRM com-
pared with transplantations from matched related donors.
These results are surprising, considering the comparable
outcomes reported for MUD with MRD in AML patients
[17,18]. Recently, a Center for International Bone Marrow and
Transplant Research analysis with 701 MDS patients who
underwent transplantation between 2002 and 2006 also
showed similar ﬁndings and reported 10% to 20% lower rates
of OS with MUD and 7/8 MUD compared with MRD patients.
They also showed no difference in the incidence of relapse,
but TRMwas increased inMUD patients comparedwithMRD
[19]. The selection criteria for MUD have changed over the
years, which should lead to an improvement in MUD out-
comes. When we looked at our results after 2005, the year
we started high-resolution molecular typing for both class I
and class II antigens, we observed a decrease in the differ-
ence between MUD and MRD transplantation. Although the
3-year OS was 20% inferior with MUD compared with MRD
before 2005, this difference was down to 10% after 2005.
These data suggest that donor type should be considered
when planning HSCT, but unrelated donor transplantations
do offer an opportunity for long-term survival in selected
patients with high-risk MDS, especially with strict matching
criteria.
We did not observe different outcomes after various
therapy approaches before HSCT. The untreated group was
unique in that it included mostly t-MDS patients who were
closely monitored for other hematologic malignancies and
who underwent HSCT mostly with an MRD, within a median
of 5 months after MDS diagnosis. Among the patients who
hadMDS therapy before HSCT, the 122 patients who received
only HMAs were older and were included in more high-risk
groups by r-IPSS. Despite those poor prognostic features, the
HMA group had similar post-transplantation outcomes
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those presented in a recent report by Damaj et al. [20]. More
importantly, despite the signiﬁcantly older age of patients in
the HMA cohort, TRM was not higher than observed in
younger patients of the untreated group. Therefore, our re-
sults and previously published data [20-23] support the
notion that using HMA inMDS patients before HSCT is a valid
therapeutic approach that renders RI, EFS, and OS similar to
those achieved by chemotherapy.
In this analysis, cytoreduction with any therapy approach
to achieve CR did not lead to improved RI, EFS, or OS. Even
achievement of a deeper level of remission with normal
karyotype at transplantation was not associated with
decreased RI and improved survival in patients with cyto-
genetic abnormalities at diagnosis. Our results were inter-
esting, in that a BM blast count  5% at HSCT was a poor
prognostic factor for relapse, in addition to high-risk cyto-
genetics, in the multivariate model; although, that was not
the case for OS and EFS. One should remember that CR
criteria by IWG is very strict and effective cytoreduction may
not be associated with achieving CR in all the cases. In our
cohort, the patients who had previous MDS therapy had a
median BM blast count of 3% at HSCT, but only 25% of those
were in CR. These results, although they must be interpreted
with caution because of the limitations inherent in a retro-
spective study design, are unable to answer the question of
the overall beneﬁt of MDS therapy before HSCT, but they also
do not show an advantage of pretransplantation therapy.
The value of prior cytoreductive therapy is still not clear in
the absence of randomized trials. A randomized study from
the European Group for Blood and Marrow Transplantation
had to be stopped because of slow recruitment. Retrospec-
tive single-center studies failed to show deﬁnitive evidence
of a survival beneﬁt associated with chemotherapy therapy
before HSCT, with additional selection bias as a result of the
difﬁculty accounting for patient drop-out (ie, patients who
received induction chemotherapy but never received HSCT
because of death or toxicity) [24,25]. Whether treatment
with HMA, which has a good toxicity proﬁle, before HSCT
offers an advantage also remains to be established. In recent
analyses, there was no beneﬁt to HMA when HMA was
compared with no treatment before HSCT [21]. Similarly,
patients with response and/or fewer than 5% BM blast after
HMAs did not have improved transplantation outcomes
compared with nonresponders [20,26]. Despite the paucity
of data showing improved survival after HSCT, pre-
transplantation therapy is commonly used. In our series,
approximately 80% of our patients received HMA before
transplantation after 2005, when HMAs became available.
Given the risk of losing transplantation eligibility as a result
of death or treatment-related toxicity, HMAs can be a better
option, compared with chemotherapy, for patients in whom
transplantation is contemplated. On the other hand, our and
previous results suggest that not only cytoreductive therapy
should be further addressed in prospective controlled clinical
trials, but also the paradigm of treatment selections in MDS
patients may need to change. Considering the aim of pre-
transplantation cytoreductive therapy is to decrease relapse
and improve survival, other strategies of intensifying con-
ditioning regimens [27] and post-transplantation mainte-
nance [28], with recent encouraging outcomes, should be
explored further.
In conclusion, this analysis shows MK and the 5-group
cytogenetic classiﬁcation can deﬁne prognostic groups for
OS, EFS, and RI after HSCT. Patients with MKþ or “verypoor” cytogenetic with poorer prognosis after HSCT should
be the target of future studies with innovative strategies to
improve transplantation outcomes. In this analysis, we
could not demonstrate a beneﬁt of pretransplantation
cytoreductive therapy using HMA or chemotherapy on the
outcome of hematopoietic transplantation. Prospective
controlled trials are needed to address optimal initial
management of patients with MDS who are candidates for
hematopoietic transplantation. Until that data are available,
given the acceptable toxicity, potential for cytoreduction
and acceptable TRM, HMAs may have an advantage over
chemotherapy for MDS patients who are transplantation
candidates and need further therapy.
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